ABUS vs H · P/E 5.4, rev $6.2M vs rev $6.65B
Arbutus Biopharma Corp (ABUS) versus Hyatt Hotels Corporation (H) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Hyatt Hotels Corporation (H) is a lodging company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported H revenue for 2024-12-31 was $6.65B. Net income was $1.30B. Revenue was down 0.3% from 2023-12-31 to 2024-12-31. H currently screens at market cap $17.08B.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. H currently screens at market cap $17.08B.
Not investment advice. Open the ABUS and H stock pages for the full models.
Not investment advice.